Results 51 to 60 of about 70 (68)

Oteseconazole: An Advance in Treatment of Recurrent Vulvovaginal Candidiasis

Future Microbiology, 2021
Paul Nyirjesy, Jack Sobel
exaly  

Recurrent Vulvovaginal Candidiasis: An Immunological Perspective

Microorganisms, 2020
Martin Jaeger, Simone Moorlag, Mariolina Bruno   +2 more
exaly  

Vulvovaginal Candidiasis: A Current Understanding and Burning Questions

Journal of Fungi (Basel, Switzerland), 2020
Junyan Liu, Brian Peters, Zhenbo Xu
exaly  

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy

Drug Design, Development and Therapy, 2023
exaly  

Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis

Frontiers in Immunology, 2022
, Shi Dongmei
exaly  

Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis

SAGE Open Medicine, 2022
Mark Martens
exaly  

Vulvovaginal candidosis

Lancet, The, 2007
Jack Sobel
exaly  

The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause

Climacteric, 2018
Nick Panay, Rossella Nappi, Santiago Palacios   +2 more
exaly  

Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study

American Journal of Obstetrics and Gynecology, 2004
Paul Nyirjesy, Betsy Foxman, Jack Sobel   +2 more
exaly  

Vulvovaginal Candidosis: Current Concepts, Challenges and Perspectives

Journal of Fungi (Basel, Switzerland), 2020
Herbert Kiss, Alex Farr, Philipp Foessleitner   +2 more
exaly